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Abstract
Background: High-intensity donation is a risk factor for iron 
deficiency in blood donors. Interdonation intervals for whole 
blood (WB) donation and double unit red blood cell apher-
esis (2RBC) vary among countries. We retrospectively evalu-
ated the course of haemoglobin (Hb) and ferritin values in 
men regularly donating WB 4 times a year or 2RBC twice a 
year (i.e., maximal frequency) over a period of 48 months. 
Methods: Data of male donors with 16 WB or 8 2RBC con-
secutive donations were analysed. The minimum Hb levels 
for WB donation and 2RBC apheresis (collection of 360 mL 
RBC) were 135 and 140 g/L, respectively. There was no lower 
limit set for ferritin, and no iron was substituted. Results: We 
identified 294 WB (mean age 53 years, SD 11) and 151 2RBC 
donors (mean age 48 years, SD 9) who donated at a mean 
interval of 97 (SD 18) and 201 days (SD 32), respectively, be-
tween January 1, 2008, and December 31, 2013. At baseline, 
Hb and ferritin values were lower in WB donors compared to 
2RBC donors, with a mean Hb of 153 g/L (SD 13) versus 159 
g/L (SD 8) and a mean ferritin of 44 μg/L (SD 52) versus 73 
μg/L (SD 56; p < 0.001 for both parameters), respectively. Fer-
ritin was below 15 μg/L in 40 WB (14%) and in 4 (3%) 2RBC 
donors. In WB donors, the mean Hb levels at baseline versus 
last donation showed no significant difference (153 vs. 152 
g/L, p = 0.068), whereas the mean ferritin levels decreased 
significantly (44 vs. 35 μg/L, p < 0.001). The 2RBC donor 
group displayed a statistically different decrease in both the 
mean Hb levels (158 vs. 157 g/L; p < 0.05) and the mean fer-
ritin levels (73 vs. 66 μg/L; p = 0.052). The lowest Hb was mea-
sured at the 11th WB donation (152 g/L; p < 0.05) and at the 
4th 2RBC apheresis (157 g/L; p < 0.05). There was no deferral 
due to low Hb at any time. The lowest ferritin was shown at 
the 4th WB (37 μg/L) and at the 3rd 2RBC donation (60 μg/L), 
respectively. At the last visit, ferritin was below 15 μg/L in 23 
WB donors (8%) and in 2 2RBC donors (1%). Conclusions: 
High-intensity male donors with an interdonation interval of 
12 weeks for WB donation and 24 weeks for 2RBC apheresis 
maintain acceptable Hb levels and, after an initial decline, 
stable ferritin levels despite ongoing blood donation.
© 2020 The Author(s)
Published by S. Karger AG, Basel
Introduction
Due to the decreasing pool of active blood donors and 
the overall aging of the general population, one major 
challenge for blood banks will be to ensure a sufficient 
blood supply to patients [1]. To tackle this task, one strat-
egy is increasing the frequency of blood donations by 
shortening the interdonation interval and thus collecting 
a greater number of blood units per donor. However, 
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shorter intervals may expose blood donors to a higher risk 
of iron deficiency and deferral due to low haemoglobin 
(Hb) [2–4].
Iron deficiency is a major challenge for maintaining an 
active blood donor pool [5–7]. In the INTERVAL trial, the 
only randomised study conducted on the interdonation 
interval in whole blood (WB) donors, a blood donation 
frequency higher than the standard in the UK (12 weeks 
for men, 16 weeks for women) increased the number of 
blood products but also resulted in more frequent dona-
tion-related symptoms, deferrals due to low Hb and iron 
deficiency [5]. Strategies to prevent low Hb and iron defi-
ciency anaemia, including a reduction of donation fre-
quency, were implemented in many single institutions [8, 
9] and are currently discussed at a regulatory level [10].
On the other hand, the introduction of longer interdo-
nation intervals can have a negative impact on blood pro-
curement [11], depending on the extent of the interval 
prolongation. Although the interval between donations is 
one of the strongest predictors of iron deficiency [12], 
current practices vary among national blood services as 
well as single blood collection facilities [13]. In the United 
States, both males and females are allowed to donate WB 
every 8 weeks and double red blood cells (2RBC) by 
apheresis every 16 weeks [14]. The European Directives 
require the same minimal interdonation interval (8 
weeks) for WB donors and set a total limit of 6 and 4 do-
nations yearly for males and females, respectively. At the 
same time, the Directives recommend 4 and 3 donations 
yearly for males and females, respectively, not to be ex-
ceeded. The minimum interval for 2RBC collection is 4 
and 6 months for men and women, respectively [15].
Women of childbearing age, young persons aged 16–
18 years, and high-frequency donors are at the greatest 
risk of iron deficiency. These donors are more often de-
ferred due to low Hb and are more likely to cease donat-
ing blood permanently [7, 16]. However, there appears to 
be a small, not well defined subgroup of frequent donors 
who are able to maintain normal Hb levels despite low 
iron stores and repeated donations at the shortest interval 
possible [17]. 
In Switzerland, the minimum interval for WB dona-
tions is 10 weeks for both men and women, but following 
the European recommendations, the practice is to allow 
a maximum of 4 and 3 donations yearly, respectively. The 
interdonation interval for 2RBC apheresis is set at a “pro-
tective” frequency of 24 weeks for both sexes.
At our centre, the routine measurement of ferritin was 
implemented along with the introduction of 2RBC apher-
esis in January 2004. We performed a retrospective anal-
ysis of Hb and ferritin measurements in male blood do-
nors who donated WB or 2RBC by apheresis at the max-
imum donation frequency of 4 and 2 times yearly, 
respectively, over a period of 48 months. The aim of the 
study was to describe the course of Hb and ferritin and 
the occurrence of deferrals due to low Hb in these high-
intensity blood donors. 
Materials and Methods
Subjects and Eligibility Criteria
In this study, regular male WB donors aged 18–75 years and 
2RBC donors aged 18–65 years were included. Donor selection 
criteria in accordance with the Swiss regulations and the European 
Directives had to be fulfilled. Regarding the donors’ age limits in 
Switzerland, eligibility of WB donors older than 65 years is subject 
to approval by a blood donation physician and may be extended 
up to the age of 75. These donors are required to undergo regular 
medical evaluations every 2 years assessing their individual risk 
profile. The upper age limit for donations by apheresis is 65 years.
All subjects in the 2RBC group must have at least 1 WB donation 
prior to their first 2RBC apheresis, and many of them were regular 
WB donors previously. Conversely, only a few WB donors had do-
nated 2RBC by apheresis prior to the inclusion in the study. Com-
plete data on the donation history was not available for every donor.
We searched our files for blood donors who donated at the 
shortest interval (12 weeks for WB and 24 weeks for 2RBC) and 
found that the highest donation frequency was maintained for a 
period of 48 months by the majority of these subjects, and there-
fore focused our analysis on this period. Thus, we identified 445 
donors (3.8% of all male donors) who underwent 16 consecutive 
WB donations and 8 consecutive 2RBC apheresis over 48 months. 
Platelet apheresis donors, those with hereditary haemochro-
matosis or any HFE gene mutation, if known, were excluded from 
the analysis. Also excluded were procedures that were not com-
pleted for any reason (i.e., because of local haematoma or technical 
issues).
The eligibility criteria for WB donors included a minimum Hb 
level of 135 g/L and a minimum body weight of 50 kg, while the 
2RBC apheresis donors were required to have a Hb of at least 140 
g/L and a body weight of at least 70 kg, approximately correlating 
with a total blood volume of 5 L or more. 
Ferritin levels were not included in the eligibility criteria nor 
were they used for the selection of 2RBC donors. Thus, volunteers 
were accepted for WB or 2RBC donation independently of their 
iron stores. No iron supplementation was provided to donors at 
any time, but donors were not systematically asked whether they 
had any symptoms of iron deficiency or were taking iron supple-
ments. 
Laboratory Testing
At each visit, a complete blood count was performed from a 
pre-donation finger prick sample on a haematology analyser (Sys-
mex K-4500, Sysmex Digitana AG, Horgen, Switzerland). Ferritin 
was also measured at each visit from a venous blood sample col-
lected at the beginning of each procedure with a chemilumines-
cence assay (Architect ci8200, Abbott Diagnostics, Abbott Park, 
IL, USA). Results were available the following day. Our ferritin 
reference ranges for men were 30–300 µg/L.
Donation Procedures, RBC, and Iron Loss
For conventional WB donation, a volume of approximately 450 
mL blood was collected with an additional 30 mL blood (approxi-
mately 14 mL RBC) for routine testing. The corresponding total 
iron loss was about 240–260 mg, considering a loss of about 1 mg 
per 1 mL RBC [18]. The minimum interdonation interval was 12 
weeks.
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2RBC apheresis was performed with an ALYX device (Fenwal-
Baxter, Zürich, Switzerland) programmed for the collection of 360 
mL RBC, corresponding to approximately the RBC volume of two 
WB donations minus 40 mL. Taking into account additional RBC 
losses due to sampling for routine tests (about 30 mL WB, 14 mL 
RBC) as well as residual cells in the collection set (a median of 26 
mL WB, about 11 mL RBC) [19], we calculated that the amount of 
iron lost at each completed 2RBC collection was approximately 
385 mg. Thus, the amount of iron removed during each 2RBC 
apheresis (360 mL) was about 148% of that removed with each WB 
donation. The interval between two 2RBC aphereses was 24 weeks. 
No plasma or platelets were concomitantly collected. 
Statistical Analysis
We used generalised estimating equation models of the Gauss-
ian family with robust SEs in order to assess the temporal trajecto-
ries of WB and 2RBC donors’ Hb and ferritin over 16 and 8 dona-
tions, respectively. Baseline Hb and ferritin at first donation were 
compared to subsequent measurements. Temporal changes in out-
comes unadjusted and adjusted for age were reported both in the 
whole study cohort and in quartile groups defined by different Hb 
and ferritin values. Statistical significance was established at p < 
0.05. A Stata version 15.1 (StataCorp, College Station, TX, USA) 
was used for all statistical analyses.
Results
Between January 1, 2008, and December 31, 2013, the 
overall number of WB collections at our centre was 82,324 
from 21,700 donors. Of these, 11,772 were males (54% of 
all WB blood donors), who provided 52,721 WB dona-
tions (64% of all WB donations). The 2RBC donor pool 
comprised 495 male subjects and no females. The overall 
Table 1. Characteristics of the study population, number of donations and haemoglobin and ferritin values at the 
first and last donation of the observation period
WB donors 2RBC donors p value
Donors, n 21,700 495
Male donors, n (%) 11,772 (54)a 495 (100)b
Included in the study, n (%) 294 (1.3)a 151 (31)b
Donations, n 82,324 2,394
From male donors, n (%) 52,721 (64) 2,394 (100)
From donors included in study, n (%) 4,704 (9) 1,208 (50)
Donations prior to study, mean (SD), n 68 (40)c 40 (30)d <0.001f
Mean interval (SD), days 97.4 (17.8) 201.0 (32.2) <0.001f
Age, median (range), years
At 1st visit 56 (20–70) 48 (23–63) <0.001g
At last visit 60 (24–74) 52 (27–67)
Hb
At 1st visit, mean (SD), g/L 153 (13) 159 (8) <0.001f
At last visit, mean (SD), g/L 152 (8) 157 (9) <0.001f
Subjects with low Hbe, n 0 0
Ferritin, mean (SD), µg/L
At 1st visit 44 (52) 73 (56) <0.001f
At last visit 35 (25) 66 (55) <0.001f
Ferritin at 1st visit, n (%) <0.001h
≥100 µg/L 18 (6) 38 (25)
51–99 µg/L 48 (16) 49 (32)
31–50 µg/L 85 (29) 44 (29)
16–30 µg/L 103 (35) 16 (11)
≤15 µg/L 40 (14) 4 (3)
Ferritin at last visit, n (%) <0.001h
≥100 µg/L 5 (2) 32 (21)
51–99 µg/L 80 (27) 74 (49)
31–50 µg/L 87 (30) 27 (18)
16–30 µg/L 99 (33) 16 (11)
≤15 µg/L 23 (8) 2 (1)
a Of the whole WB donors population. b Of the whole 2RBC donors population. c Out of these, 5 donations 
were 2RBC apheresis. d Out of these, 43 donations were 2RBC apheresis. e Lower than 135 g/L for WB donors 
and lower than 140 g/L for 2RBC donors. f Independent sample t test. g Wilcoxon rank-sum test. h Fisher’s exact 
test.
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number of 2RBC aphereses performed within the study 
period was 2,394 (Table 1).
Characteristics of the Study Cohort and Values at the 
First and at the Last Donation (Table 1)
In the study cohort, there were 294 WB donors (1.3% 
of all male WB donors, 66% of the study population) and 
151 2RBC donors (31% of all 2RBC donors, 34% of the 
study population). The cohort donors provided a total of 
4,704 WB donations at a mean interval of 97.4 days (SD 
17.8) and 1,208 2RBC aphereses at a mean interval of 201 
days (SD 32.2). 
At baseline, the 2 groups were different with respect to 
median age (WB donors: 56 years, range 20–70 years; 
2RBC donors: 48 years, range 23–63 years; p < 0.001) and 
to the mean number of donations performed prior to the 
first procedure in the study (68 in WB donors and 40 in 
2RBC donors; p < 0.001). In addition, both Hb (mean 153 
g/L, SD 13 vs.159 g/L, SD 8) and ferritin (mean 44 μg/L, 
SD 52 vs. 73 μg/L, SD 56) were significantly lower in WB 
donors (p < 0.001 for both parameters).
While all donors fulfilled the Hb requirements, a broad 
range of ferritin values was observed in both groups. Fer-
ritin was above 100 µg/L in 25% of 2RBC donors, but in 
only 6% of WB donors. The majority of WB donors (35%) 
had ferritin levels between 16 and 30 µg/L, while most 
2RBC donors (32%) had values between 51 and 99 µg/L. 
Forty WB donors (14%) but only 4 2RBC donors (3%) 
had ferritin values below 15 µg/L indicating profound 
iron deficiency. Of the donors with very low ferritin val-
ues, those donating WB had a mean of WB donations 
prior to the study slightly lower than the overall mean of 
the WB group, while the 4 2RBC donors had a mean of 
previous WB donations that was higher than that of the 
whole 2RBC group (data not shown). Neither group had 
donated 2RBC by apheresis before the inclusion to the 
study.
At the last visit, the proportion of subjects with ferritin 
values between 16 and 30 µg/L slightly decreased (to 33%) 
in the WB group and remained unchanged in the 2RBC 
group. The percentage of donors with values below 15 
µg/L dropped in both WB (8%) and 2RBC donors (1%).
Fig. 1. Course of haemoglobin and ferritin in whole blood (a–b) and double red blood cell donors (c–d). Values are adjusted for age.
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Course of Hb and Ferritin
Figure 1a–d shows the values of Hb and ferritin over a 
period of 48 months adjusted for age. In WB donors, Hb 
declined from 153 to 152 g/L (p = 0.068) and ferritin from 
44 to 35 μg/L (p < 0.001), while in 2RBC donors Hb and 
ferritin decreased from 158 to 157 g/L (p < 0.05) and from 
73 to 66 μg/L (p = 0.052), respectively. Hb and ferritin dif-
ferences between donation groups remained stable, with 
substantially higher levels of both Hb (mean 5 g/L) and 
ferritin (mean 26 μg/L) in 2RBC donors. Compared to Hb 
at baseline, in WB donors a statistically significant Hb 
drop was observed from the 11th visit on (152 g/L, p < 
0.05), that is, approximately after 33 months. Corre-
spondingly, the lowest Hb values in 2RBC donors were 
observed from the 4th donation on (157 g/L, p < 0.05), 
that is, approximately after 24 months. Hb declined fur-
ther in both groups until the 15th (minimal value: 151 
g/L) and 7th donation (minimal value: close to 157 g/L), 
respectively, with an increasing trend afterwards. How-
ever, the Hb levels have never reached their baseline levels 
in either group within the 48 months. On average, Hb 
levels remained 5 g/L (95% CI 3.7–6.4, p < 0.001) higher 
in 2RBC donors compared to WB donors over the entire 
study period. 
Ferritin levels in WB donors decreased from 44 μg/L 
at the first visit to 35 μg/L (p < 0.001) at the last donation, 
and in 2RBC donors from 73 to 66 μg/L (p = 0.052). 
Relative to baseline, a first significant ferritin drop in 
WB donors was observed already at the 2nd donation 
(41 μg/L), after approximately 3 months, followed by a 
second decline at the 4th visit, approximately 12 months 
later (37 μg/L, p < 0.001). From there on, a parabolic 
trend was observed, with a peak at the 10th donation and 
a consecutive drop (Fig. 1b). Similarly, ferritin signifi-
cantly decreased in 2RBC donors at the 2nd donation 
(66 μg/L), after approximately 12 months, reaching the 
lowest level at the 3rd donation (60 μg/L) after 18 
months. From that point, ferritin values increased and 
reached 66 μg/L (p = 0.052) at the end of the study pe-
riod. Ferritin levels were also lower at the last visit com-
pared to those at baseline in both groups, and were on 
average higher in 2RBC donors (mean 26 μg/L; 95% CI 
19.3–32.7 μg/L; p < 0.001) over the entire observation 
period (Fig. 2b, d).
Fig. 2. Trajectories of haemoglobin and ferritin in whole blood (a–b) and double red blood cell donors (c–d) by quartile groups.
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We further assessed the trajectories of Hb and ferritin in 
quartile groups (Fig. 2a–d). For WB and 2RBC donors alike, 
we consistently found that Hb and ferritin declined most 
steeply in subjects with the highest baseline values (Q4). In 
WB donors of Q4, Hb declined in the range of 3.5–8.0 g/L, 
while in 2RBC donors, the decrease was 3.3–4.7 g/L. The 
corresponding ferritin drop was in the range of 22.5–50.1 
μg/L in WB donors and 25.5–44.6 μg/L in 2RBC donors.
Conversely, in donors with the lowest levels at first do-
nation (Q1) values tended to improve with time. More 
specifically, Hb in Q1 significantly increased in the range 
of 3.7–6.0 g/L in the WB group and of 0.2–4.5 g/L in the 
2RBC group, while the ferritin increase was in the range 
of 6.1–13.5 and 3.4–13.0 μg/L, respectively. As compared 
to Q1 and Q4, the 2 intermediate quartile groups (Q2 and 
Q3) displayed a more stable trajectory of both Hb and fer-
ritin, and values showed smaller differences from those at 
baseline. 
Discussion
This study describes the course of Hb and iron stores 
in a selected population of high-intensity male blood do-
nors undergoing regular WB or 2RBC donations at the 
shortest interdonation interval recommended in Switzer-
land. Most interestingly, these subjects did not show a 
drop in Hb below the acceptance limit over the 4 years’ 
period of donating on a regular basis regardless of their 
iron stores including profound iron deficiency (ferritin 
below 15 µg/L).
Previous large studies reported ferritin values lower 
than 10–12 µg/L in a substantial proportion of regular 
blood donors, ranging from 15% in the RISE study [20] 
to over 26% at our centre [9]. In the vast majority of WB 
donors, a minimum interval of 8 weeks, as currently ad-
opted in the United States, is not sufficient for restoring 
Hb and iron stores, and is often associated with deferrals 
due to low Hb unless iron supplementation is given [12]. 
However, reducing the maximum donation frequency 
may not be alone sufficient to prevent relevant iron defi-
ciency in blood donors. As shown by our data, despite a 
lower donation frequency in Switzerland compared to 
that of many other countries, ferritin values below 30 
µg/L were found in over one-third (35%) of male donors 
and about 10% had values below 15 µg/L.
On the other hand, Mast et al. [17] described a self-se-
lected population of 138 high-intensity male and female 
blood donors who did not develop anaemia despite very 
low ferritin levels. The mechanism of “resistance” to iron 
deficiency anaemia observed in these “superdonors” was 
not completely elucidated through extensive evaluation, 
including hepcidin measurement and testing for HFE mu-
tations [17]. It is possible that a significant proportion of 
the donors selected for our study may share some charac-
teristics of the above-mentioned superdonors. Considering 
that in the study by Mast et al. [17] the interdonation inter-
val was 8 weeks, most subjects in our cohort may possibly 
tolerate even more frequent blood donation schedules than 
currently recommended in Switzerland (4 WB donations 
yearly). Similar postulations may apply to the interval 
 between two 2RBC aphereses. Our procedure for 2RBC 
apheresis (collection volume of 360 mL and interval of 24 
weeks) appears to be particularly protective regarding iron 
loss. Although previous studies showed an insufficient re-
covery of iron stores with intervals of 16 weeks in the ab-
sence of iron supplementation [21, 22], it is possible that 
many of the 2RBC donors in our cohort may tolerate apher-
eses at a 16-weeks’ frequency without developing low Hb. 
With this respect, it is important to consider the differenc-
es in baseline characteristics of WB and 2RBC donors and 
also in the types of donation described in our study. 2RBC 
donors were younger, had higher Hb and ferritin levels at 
baseline, and had a lower number of previous blood dona-
tions (a mean of 40 vs. 68 in WB donors). These differenc-
es may be explained by the more recent recruitment of 
2RBC donors following the introduction of 2RBC aphere-
sis at our centre in 2004 as well as by different Hb cut-offs 
required for the 2 types of collections (140 g/L for 2RBC 
apheresis vs. 135 g/L for WB donation). Hb and ferritin 
levels in 2RBC donors remained higher throughout the ob-
servation period, which is most probably explained by the 
fact that the RBC volume and iron amount lost with 2RBC 
apheresis are less than that of two WB donations. Another 
interesting finding is that 2RBC donors were much more 
likely to donate at the maximum frequency compared to 
WB donors (31 vs. 1.3%). This data does not support the 
concern that a longer interdonation interval may induce a 
loss of motivation and a lower donor return [23]. 
The overall changes of Hb and ferritin observed with-
in our study were similar in both types of blood dona-
tions. An initial drop in the values was followed by an 
upward trend later, even though the baseline levels of nei-
ther parameter were regained in neither group by the end 
of the study. Gonzàlez et al. [24] described a very similar 
course of ferritin in 2RBC donors over regular apheresis 
at an interval of 24 weeks. Also in that study, ferritin lev-
els recovered after an initial significant decline, and so the 
authors concluded that ferritin is possibly not the most 
important parameter for 2RBC donor selection. 
Since we included only experienced blood donors in 
the study, the number of previous donations had an im-
pact on Hb and ferritin values at the baseline visit, but 
complete data on the donation history could not be re-
trieved for each donor. Therefore, we chose to analyse re-
sults separately in groups defined not by the number of 
previous donations but by baseline Hb and ferritin levels 
(quartiles). Particularly interesting is the favourable 
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course of Hb and ferritin in subjects starting with the low-
est values (Q1) in both donation groups. One could hy-
pothesise that this subgroup in particular shares some 
metabolic characteristics of the “superdonors.” Identify-
ing these subjects prospectively in a given donor pool is 
probably not possible. Indeed, in our study these subjects 
represented only a very small fraction of the WB and 
2RBC donors (1.3 and 2.5%, respectively). However, we 
believe that these numbers underestimate the actual pro-
portion of potential high-frequency donors who may pro-
vide a highest yield of blood products in the long-term. 
This aspect has a particular relevance when considering 
the generally declining number of active blood donors and 
the overall observed low donation frequency. At our cen-
tre, active blood donors represent about 4.1% of all poten-
tially eligible adults living in our region, and give on aver-
age 1.5 donations yearly, for a total of about 15,000 WB 
donations yearly. The number of 2RBC apheresis is steep-
ly declining (over 300 per year in 2008–2013 and 108 in 
2018). During the period of our analysis, from 2008 to 
2013, there was approximately 1 WB donation and 0.8 
2RBC donations per year for the total donor population. 
As also discussed by Di Angelantonio et al. [5], identifying 
donors who best tolerate more frequent donations would 
provide a valuable tool for enabling more flexible interdo-
nation intervals. Since it is evident that no fixed interval 
can be applied to all donors alike, defining individualised 
donation frequencies may be the most appropriate ap-
proach for retaining and protecting donors. However, 
such a strategy requires a more precise characterisation of 
the actual risk for iron deficiency and low Hb in distinct 
blood donor groups, as we attempted in our analysis. 
Based on our observations, Hb and ferritin values dis-
play different courses in distinct groups of regular blood 
donors, which may have potentially significant implica-
tions for donor care. First, it allows for a more correct 
interpretation of the initial variations of values (e.g., 
steeper drop of ferritin in subjects starting at higher levels, 
as shown by our data). Second, it demonstrates that low 
ferritin does not necessarily impact sustained blood do-
nation and requires no intervention in subjects with suf-
ficient Hb levels. With this respect, however, it would be 
important to evaluate specifically the presence of iron de-
ficiency-related symptoms in donors with low ferritin 
levels. It is important to consider that prolonged iron de-
ficiency even in the absence of symptoms and despite 
normal Hb levels may possibly negatively impair donors’ 
health. Although the long-term effects of iron deficiency 
without anaemia are still unclear and are most probably 
influenced by individual differences, repetitive blood do-
nation in iron-depleted subjects may represent a poten-
tial harm. In addition, recent data, although not conclu-
sive, indicate that also the quality of RBC products can be 
altered by the donor’s low iron stores. In the study by 
Kanias et al. [25], donation intensity and ferritin levels 
correlated negatively with the RBC susceptibility to oxi-
dative haemolysis during storage, but haemolysis was also 
mitigated if the donor received iron substitution. Anoth-
er study in animal models demonstrated that RBC col-
lected from mice with iron deficiency had a significantly 
shorter survival during storage and after transfusion [26]. 
A routine ferritin measurement creates undoubtedly 
valuable data that may help optimise donation frequency 
in individual donors [6]. This approach however cannot 
be easily put into practice in all blood donation facilities 
as it has logistic and financial implications. Prediction 
models for assessing the likelihood of donors’ deferral 
due to low Hb using previous Hb levels and disregarding 
ferritin have been proposed [2, 6]. These tools may prove 
helpful to identify potential high-frequency donors. In 
our opinion, further studies are needed to validate such 
models in large cohorts and in different donor groups. 
Our study has the limitations of a retrospective analysis. 
In addition, the study population is small and has clear se-
lection bias. All subjects of the cohort were males, the vast 
majority were middle-aged with very few young donors, 
and all were experienced donors with a variable number of 
previous donations. Thus, our results cannot be generalised 
to other blood donor groups, such as females and in par-
ticular pre-menopausal women and donors younger than 
25 years. It is also not known with certainty whether some 
donors of our cohort took iron supplements without our 
knowledge, and information on symptoms of iron deficien-
cy was not systematically collected. On the other hand, the 
homogeneous characteristics of the study cohort as well as 
the consistency of management of donors over time repre-
sent the strengths of our analysis.
In conclusion, Hb and ferritin values reflect character-
istic patterns in high-frequency male WB or 2RBC do-
nors over time and indicate the possibility of increasing 
donation frequency in a subgroup of subjects, with clear 
advantages on the procurement of blood products. 
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